Latest Us Market News

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

ImpediMed Limited reported a record A$3.4 million revenue in Q3 FY25, bolstered by a surge in Annual Recurring Revenue and a strategic sales leadership change aimed at accelerating SOZO platform adoption.

SRJ Technologies reports a 47% drop in Q1 cash receipts but secures significant new contracts and advances a strategic leadership transition aimed at stabilising growth.

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Pacific Edge’s Cxbladder Plus and Triage 1 diagnostic tests are set for significant Medicare reimbursement increases, potentially reshaping the company’s US market prospects.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.

Nova Eye Medical reported a 27% rise in Q3FY25 sales excluding China, driven by record US performance and a sharp reduction in glaucoma segment losses. The company confirmed FY25 revenue guidance and unveiled plans to expand its iTrack™ technology into ocular drug delivery.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Syrah Resources halts production at its Balama graphite mine amid ongoing protests while advancing its US-based Vidalia anode material facility, securing a significant $165 million US tax credit and forging key offtake deals.

RMA Global Limited reported a robust Q3 FY25, achieving a 21% revenue increase to $5.5 million and marking its third consecutive quarter of positive operating cash flow, driven by US market expansion and the strategic acquisition of Curated Social.

Aroa Biosurgery reports a second consecutive quarter of positive operating cash flow and record sales for its Myriad product line, while maintaining full-year FY25 revenue and EBITDA guidance.